DMAA
Income statement / Annual
Last year (2024), Drugs Made In America Acquisition Corp. Ordinary Shares's total revenue was $0.00,
and the percentage change from the previous year is not available.
In 2024, Drugs Made In America Acquisition Corp. Ordinary Shares's net income was -$479.73.
See Drugs Made In America Acquisition Corp. Ordinary Shares,s key income statements, including revenue, expenses, profit, and income.
Period |
FY-2024
|
Period Ended |
12/31/2024 |
Operating Revenue |
$0.00 |
Cost of Revenue |
$0.00
|
Gross Profit |
$0.00
|
Gross Profit Ratio |
0
|
Research and Development Expenses |
$0.00
|
General & Administrative Expenses |
$479.73
|
Selling & Marketing Expenses |
$0.00
|
Selling, General & Administrative Expenses |
$479.73
|
Other Expenses |
$0.00
|
Operating Expenses |
$479.73
|
Cost And Expenses |
$479.73
|
Interest Income |
$0.00
|
Interest Expense |
$0.00
|
Depreciation & Amortization |
$479.73
|
EBITDA |
$0.00 |
EBITDA Ratio |
0
|
Operating Income Ratio |
0
|
Total Other Income/Expenses Net |
$0.00
|
Income Before Tax |
-$479.73
|
Income Before Tax Ratio |
0
|
Income Tax Expense |
$0.00
|
Net Income |
-$479.73
|
Net Income Ratio |
0
|
EPS |
-0.056 |
EPS Diluted |
-0.056 |
Weighted Average Shares Out |
$8,571.00
|
Weighted Average Shares Out Diluted |
$8,571.43
|
Link |
|